BTCY - Biotricity: Equipping Doctors  Empowering Patients Enriching Shareholders

• BTCY continues to win new business at a rapid pace, with current quarterly revenue likely to be double revenue reported just two quarters ago, well ahead of management’s past guidance.
• Reduced reimbursement rates for extended holter have no impact on BTCY, unlike the negative impact it has for competitors.
• BTCY is seeking to uplist to a major exchange sooner than later, which will provide more exposure and better liquidity.
• An app currently under development by BTCY could blow the top off current management guidance and analyst estimates.
• While there are certainly risks, the stock could conceivably be a 5-bagger over the next 2-3 years.

For further details see: